Since inception, Natus has been at the forefront of innovation in the healthcare solutions, focusing on the diagnosis and treatment of central nervous and sensory system disorders for both adults and pediatrics.

Recognizing the company as a category leader, ARCHIMED took Natus private in 2022 to initiate a pivotal transformation: the strategic separation of the Neuro and Sensory divisions.

Headquartered in Chicago (US) and Copenhagen (Denmark), Natus Sensory is now a leading player in the global sensory diagnostics market, reaching over 120 countries. Natus Sensory’s offerings include products for adult hearing, vision, and vestibular assessment, including computer-based audiological, otoneurologic, and vestibular instrumentation for hearing care professionals. In addition, Natus Sensory’s business provides products for performing hearing and vision screenings for pediatrics including newborns, as well as managing jaundice and live video streaming of infants in neonatal intensive care units.